Literature DB >> 29177461

Rigorous Clinical Trial Design in Public Health Emergencies Is Essential.

Susan S Ellenberg1, Gerald T Keusch2, Abdel G Babiker3, Kathryn M Edwards4, Roger J Lewis5, Jens D Lundgren6, Charles D Wells7, Fred Wabwire-Mangen8, Keith P W J McAdam9.   

Abstract

Randomized clinical trials are the most reliable approaches to evaluating the effects of new treatments and vaccines. During the 2014-2015 West African Ebola epidemic, many argued that such trials were neither ethical nor feasible in an environment of limited health infrastructure and severe disease with a high fatality rate. Consensus among the numerous organizations providing help to the affected areas was never achieved, resulting in fragmented collaboration, delayed study initiation, and ultimately failure to provide definitive evidence on the efficacy of treatments and vaccines. Randomized trials were in fact approved by local ethics boards and initiated, demonstrating that randomized trials, even in such difficult circumstances, are feasible. Improved planning and collaboration among research and humanitarian organizations, and affected communities, in the interepidemic periods are needed to ensure that questions regarding the efficacy of vaccines and treatments can be definitively answered during future public health emergencies.

Entities:  

Mesh:

Year:  2018        PMID: 29177461      PMCID: PMC5905619          DOI: 10.1093/cid/cix1032

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  39 in total

1.  What makes clinical research ethical?

Authors:  E J Emanuel; D Wendler; C Grady
Journal:  JAMA       Date:  2000 May 24-31       Impact factor: 56.272

2.  A new era of unapproved drugs: the case of Abigail Alliance v Von Eschenbach.

Authors:  Peter D Jacobson; Wendy E Parmet
Journal:  JAMA       Date:  2007-01-10       Impact factor: 56.272

3.  The clinical trial.

Authors:  A B HILL
Journal:  N Engl J Med       Date:  1952-07-24       Impact factor: 91.245

4.  Commentary: Will 20th century patient safeguards be reversed in the 21st century?

Authors:  Gregg Gonsalves; Diana Zuckerman
Journal:  BMJ       Date:  2015-03-25

5.  Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 Year.

Authors:  Rebecca L Winslow; Iain D Milligan; Merryn Voysey; Kerstin Luhn; Georgi Shukarev; Macaya Douoguih; Matthew D Snape
Journal:  JAMA       Date:  2017-03-14       Impact factor: 56.272

6.  Non-randomized controls in cancer clinical trials.

Authors:  E A Gehan; E J Freireich
Journal:  N Engl J Med       Date:  1974-01-24       Impact factor: 91.245

7.  Randomized versus historical controls for clinical trials.

Authors:  H Sacks; T C Chalmers; H Smith
Journal:  Am J Med       Date:  1982-02       Impact factor: 4.965

8.  Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia.

Authors:  Stephen B Kennedy; Fatorma Bolay; Mark Kieh; Greg Grandits; Moses Badio; Ripley Ballou; Risa Eckes; Mark Feinberg; Dean Follmann; Birgit Grund; Swati Gupta; Lisa Hensley; Elizabeth Higgs; Krisztina Janosko; Melvin Johnson; Francis Kateh; James Logue; Jonathan Marchand; Thomas Monath; Martha Nason; Tolbert Nyenswah; François Roman; Eric Stavale; Julian Wolfson; James D Neaton; H Clifford Lane
Journal:  N Engl J Med       Date:  2017-10-12       Impact factor: 91.245

Review 9.  A Systematic Review of Ebola Treatment Trials to Assess the Extent to Which They Adhere to Ethical Guidelines.

Authors:  Thomas Richardson; Andrew McDonald Johnston; Heather Draper
Journal:  PLoS One       Date:  2017-01-17       Impact factor: 3.240

10.  Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.

Authors:  Daouda Sissoko; Cedric Laouenan; Elin Folkesson; Abdoul-Bing M'Lebing; Abdoul-Habib Beavogui; Sylvain Baize; Alseny-Modet Camara; Piet Maes; Susan Shepherd; Christine Danel; Sara Carazo; Mamoudou N Conde; Jean-Luc Gala; Géraldine Colin; Hélène Savini; Joseph Akoi Bore; Frederic Le Marcis; Fara Raymond Koundouno; Frédéric Petitjean; Marie-Claire Lamah; Sandra Diederich; Alexis Tounkara; Geertrui Poelart; Emmanuel Berbain; Jean-Michel Dindart; Sophie Duraffour; Annabelle Lefevre; Tamba Leno; Olivier Peyrouset; Léonid Irenge; N'Famara Bangoura; Romain Palich; Julia Hinzmann; Annette Kraus; Thierno Sadou Barry; Sakoba Berette; André Bongono; Mohamed Seto Camara; Valérie Chanfreau Munoz; Lanciné Doumbouya; Patient Mumbere Kighoma; Fara Roger Koundouno; Cécé Moriba Loua; Vincent Massala; Kinda Moumouni; Célia Provost; Nenefing Samake; Conde Sekou; Abdoulaye Soumah; Isabelle Arnould; Michel Saa Komano; Lina Gustin; Carlotta Berutto; Diarra Camara; Fodé Saydou Camara; Joliene Colpaert; Léontine Delamou; Lena Jansson; Etienne Kourouma; Maurice Loua; Kristian Malme; Emma Manfrin; André Maomou; Adele Milinouno; Sien Ombelet; Aboubacar Youla Sidiboun; Isabelle Verreckt; Pauline Yombouno; Anne Bocquin; Caroline Carbonnelle; Thierry Carmoi; Pierre Frange; Stéphane Mely; Vinh-Kim Nguyen; Delphine Pannetier; Anne-Marie Taburet; Jean-Marc Treluyer; Jacques Kolie; Raoul Moh; Minerva Cervantes Gonzalez; Eeva Kuisma; Britta Liedigk; Didier Ngabo; Martin Rudolf; Ruth Thom; Romy Kerber; Martin Gabriel; Antonino Di Caro; Roman Wölfel; Jamal Badir; Mostafa Bentahir; Yann Deccache; Catherine Dumont; Jean-François Durant; Karim El Bakkouri; Marie Gasasira Uwamahoro; Benjamin Smits; Nora Toufik; Stéphane Van Cauwenberghe; Khaled Ezzedine; Eric D'Ortenzio; Eric Dortenzio; Louis Pizarro; Aurélie Etienne; Jérémie Guedj; Alexandra Fizet; Eric Barte de Sainte Fare; Bernadette Murgue; Tuan Tran-Minh; Christophe Rapp; Pascal Piguet; Marc Poncin; Bertrand Draguez; Thierry Allaford Duverger; Solenne Barbe; Guillaume Baret; Isabelle Defourny; Miles Carroll; Hervé Raoul; Augustin Augier; Serge P Eholie; Yazdan Yazdanpanah; Claire Levy-Marchal; Annick Antierrens; Michel Van Herp; Stephan Günther; Xavier de Lamballerie; Sakoba Keïta; France Mentre; Xavier Anglaret; Denis Malvy
Journal:  PLoS Med       Date:  2016-03-01       Impact factor: 11.069

View more
  8 in total

1.  Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Authors:  Renato D Lopes; Ariane Vieira Scarlatelli Macedo; Pedro Gabriel Melo de Barros E Silva; Renata Junqueira Moll-Bernardes; Andre Feldman; Guilherme D'Andréa Saba Arruda; Andrea Silvestre de Souza; Denilson Campos de Albuquerque; Lilian Mazza; Mayara Fraga Santos; Natalia Zerbinatti Salvador; C Michael Gibson; Christopher B Granger; John H Alexander; Olga Ferreira de Souza
Journal:  Am Heart J       Date:  2020-05-13       Impact factor: 4.749

2.  Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.

Authors:  Renato D Lopes; Ariane V S Macedo; Pedro G M de Barros E Silva; Renata J Moll-Bernardes; Tiago M Dos Santos; Lilian Mazza; André Feldman; Guilherme D'Andréa Saba Arruda; Denílson C de Albuquerque; Angelina S Camiletti; Andréa S de Sousa; Thiago C de Paula; Karla G D Giusti; Rafael A M Domiciano; Márcia M Noya-Rabelo; Alan M Hamilton; Vitor A Loures; Rodrigo M Dionísio; Thyago A B Furquim; Fábio A De Luca; Ítalo B Dos Santos Sousa; Bruno S Bandeira; Cleverson N Zukowski; Ricardo G G de Oliveira; Noara B Ribeiro; Jeffer L de Moraes; João L F Petriz; Adriana M Pimentel; Jacqueline S Miranda; Bárbara E de Jesus Abufaiad; C Michael Gibson; Christopher B Granger; John H Alexander; Olga F de Souza
Journal:  JAMA       Date:  2021-01-19       Impact factor: 56.272

3.  Evaluating Promising Investigational Medical Countermeasures: Recommendations in the Absence of Guidelines.

Authors:  Nahid Bhadelia; Lauren Sauer; Theodore J Cieslak; Richard T Davey; Susan McLellan; Timothy M Uyeki; Mark G Kortepeter
Journal:  Health Secur       Date:  2019-02-06

4.  Addressing challenges for clinical research responses to emerging epidemics and pandemics: a scoping review.

Authors:  Louise Sigfrid; Katherine Maskell; Peter G Bannister; Sharif A Ismail; Shelui Collinson; Sadie Regmi; Claire Blackmore; Eli Harriss; Kajsa-Stina Longuere; Nina Gobat; Peter Horby; Mike Clarke; Gail Carson
Journal:  BMC Med       Date:  2020-06-25       Impact factor: 8.775

5.  Evidence-Based Practical Guidance for the Antithrombotic Management in Patients With Coronavirus Disease (COVID-19) in 2020.

Authors:  Eduardo Ramacciotti; Ariane Scarlatelli Macedo; Rodrigo Bruno Biagioni; Roberto Augusto Caffaro; Renato Delascio Lopes; João Carlos Guerra; Fernanda Andrade Orsi; Marcos Areas Marques; Alfonso J Tafur; Joseph A Caprini; Andrew Nicolaides; Charles A Carter; Cyrillo Carvalheiro Filho; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

6.  Characteristics analysis for clinical study design relating to COVID-19 based on the database of ClinicalTrials.gov.

Authors:  Hanting Wu; Rongchen Dai; Peijie He; Juan Liang; Qiushuang Li; Junchao Yang; Hanti Lu; Qing Guo; Wei Mao; Conghua Ji
Journal:  Int J Infect Dis       Date:  2022-01-10       Impact factor: 12.074

7.  Monitoring clinical trials in infectious diseases.

Authors:  David L DeMets; Thomas R Fleming; Susan S Ellenberg
Journal:  J Allergy Infect Dis       Date:  2021

Review 8.  COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation.

Authors:  Wolfgang Miesbach; Michael Makris
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.